Chromosomal translocation

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Genetic variation, Gene, Genetics, Patient, NGS, 3D, Chromatin, Cancer, Genome, Workflow, Genomics, Poster, Chromosomal translocation, Mobile phone

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Bionano Laboratories Announces Publication of the Analytical Validation of its OGM-Based Laboratory Developed Test for Hematological Malignancies and Additional Multi-Site Technical Evaluation of OGM

Retrieved on: 
Tuesday, December 12, 2023
CMA, OGM, SVS, Bone marrow, Workflow, WHO, NCCN, Blood, SAN, IRB, Laboratory, University, LDT, Aberration, VAF, World Health Organization, Genome, National Comprehensive Cancer Network, Chromosomal translocation, Tier 1, KT, Diagnosis, Patient, Malignancy, Tier 2

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne.

Key Points: 
  • SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne.
  • The publication also included a multi-site peer-reviewed IRB-approved analytical validation study of OGM for the analysis of hematological malignancy samples, conducted by researchers at laboratories including Bionano Laboratories, Augusta University, University of Rochester Medical Center, and Children’s Hospital Los Angeles.
  • Subsequently, the OGM workflow was applied at the other three sites, showing high levels of reproducibility across the sites.
  • “We are pleased to see the clinical validation of Bionano Laboratories' OGM-Dx™ HemeOne LDT, analyzing its potential to serve as a first-tier cytogenetic test for heme malignancies.

BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, MSI, WES, TMB, American Securities, Salt Palace, Sequence, Epigenome-wide association study, Molecular diagnostics, Agilent Technologies, Journal, HRD, Chromosomal translocation, R, Molecular reference standards, AMP, Abstract (summary)

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.
  • During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.
  • Details of BostonGene’s presence at AMP are below:
    Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene
    Tumor molecular characterization is key for advancing precision oncology.
  • In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses.

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer

Retrieved on: 
Tuesday, August 22, 2023
Genetically modified food in the European Union, DNA, MMR, CE marking, TMB, LGR, Microsatellite instability, HRD, Bone marrow, NGS, Cancer, DNA mismatch repair, Multimedia, RNA, CNV, Drug resistance, Chromosomal translocation, MSI, Genetic testing, SNV calling from NGS data, PARP, Gene, Vaccine

TORONTO, Aug. 22, 2023 /PRNewswire/ - Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval.

Key Points: 
  • TORONTO, Aug. 22, 2023 /PRNewswire/ - Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval.
  • These approvals signify that GeneseeqPrime™ and GeneseeqPrime™ HRD are suitable for solid tumor genomic profiling, while Hemasalus™ DNA/Hemarna™ RNA is cleared for hematological cancer genomic profiling.
  • In addition to the CE-Marked GENESEEQ multi-cancer minimal residual disease detection (Shielding™ ULTRA MRD) and GENESEEQ multi-cancer early detection (CanScan™ MCED) kits introduced earlier this year , Geneseeq currently offers five CE-marked cancer genetic testing kits tailored for various clinical situations.
  • These kits will now be accessible to healthcare professionals in Europe, enabling them to formulate treatment plans for individuals affected by cancer.

Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023

Retrieved on: 
Friday, May 19, 2023
Chromosome, DNA, Therapy, Gene, CSO, Hepatitis B virus, Gene expression, Cell, Chromosomal translocation, Patient, Data, Annual general meeting, PCSK9, Society, Medicine, Vaccine, Pigment, Chroma

BOSTON, May 19, 2023 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles.

Key Points: 
  • Simultaneous epigenetic editing of three genes in primary human T cells resulted in no indels or genomic alterations, while simultaneous triple editing with a Cas9 nuclease generated significant chromosomal abnormalities
    BOSTON, May 19, 2023 /PRNewswire/ -- Chroma Medicine , Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles.
  • Chroma's epigenetic editing platform harnesses the cell's endogenous mechanism for regulating gene expression to durably modulate transcription without cutting or nicking the DNA, offering a potentially safer approach for multiplex editing.
  • Data presented today at ASGCT demonstrate the key advantages of epigenetic editing for multiplex gene regulation compared to Cas9-based approaches.
  • "We are committed to rigorously progressing our pioneering epigenetic editing technology and programs and are pleased to present data supporting the therapeutic promise of epigenetic editing for gene regulation while preserving genomic integrity."

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Chronic granulomatous disease, DNA, TRAC, Gene, CD19, Neoplasm, Bone marrow, Investigational New Drug, Deletion, Fungus, CD34, Stem cell, Health, Chromosomal translocation, Spleen, Genome, NADPH, Annual general meeting, Cancer, Cell, CGD, American Society of Gene and Cell Therapy, Society, Disease, NCF1, Vaccine, B2M

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the presentation of new preclinical data that further demonstrated the potential of Prime Editing to correct the causative mutation of chronic granulomatous disease (CGD) and preclinical data that showcased the potential application of the Prime Editing Assisted Site-Specific Integrase Gene Editing (PASSIGE™) platform to generate multiplex-edited CAR-T cells for the treatment of certain cancers and immune diseases. The data are being presented today during the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023, in Los Angeles, California.

Key Points: 
  • The data are being presented today during the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023, in Los Angeles, California.
  • “We are very pleased to present these new data for our CGD program and PASSIGE platform today at ASGCT, which underscore our belief in the breadth and potential of Prime Editing to offer curative treatments for many diseases,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine.
  • Further, while the benefits of autologous CAR-T therapies are well established, their full potential is often hindered by manufacturing and delivery challenges.
  • Prime Medicine has previously shared data from the CGD program that demonstrated the ability of Prime Editing to correct a CGD causative mutation in CD34+ cells ex vivo.

Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Sequence, Insurance, Intellectual property, Hepatitis B, HBsAg, Development, Chromosomal translocation, Patient, Cell, Eli Lilly and Company, Infant, CccDNA, Patent, Cash, University, Duchenne muscular dystrophy, Therapy, Gene, Gene editing, NK, Precision, IND, Precision BioSciences, Non-Hodgkin lymphoma, Anti-CD19 immunotoxin, Hepatitis B virus, IP, AAV, Hepatocyte, CAR, Administration, HBV, Central nervous system, Molecular Partners, NHL, CTA, State Administrative Expenses, DMD, Novartis, Vivo, OTC, Annual general meeting, Sickle cell disease, NHP, Society, Pharmaceutical industry, Vaccine, Lilly

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
  • Precision plans to provide an update on the expansion cohort as well as additional long-term follow up from the previously presented azer-cel cohorts in May 2023.
  • The Company also expects to provide a program update on seven patients treated at Dose Level 2 in May 2023.
  • Cash and Cash Equivalents: As of March 31, 2023, Precision had approximately $158 million in cash and cash equivalents.

Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
DNA, Therapy, Gene, CSO, Gene targeting, Liver, Deletion, Gene expression, Human, Hypercholesterolemia, Chromosomal translocation, Data, LDL, Annual general meeting, Cell, DNA methylation, Society, Medicine, Antibiotics, Vaccine, Chroma

BOSTON, May 2, 2023 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral data presentations that showcase the potential of its epigenetic editing platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16-20, 2023 in Los Angeles, California. The presentations include the first in vivo proof-of-concept data for Chroma's epigenetic editing platform along with data demonstrating the key advantages of epigenetic editing for multiplex gene regulation. Chroma plans to release data from additional pipeline programs at upcoming scientific conferences.  

Key Points: 
  • In vivo data provide compelling proof-of-concept for Chroma's epigenetic editing platform to enable highly efficient, specific, and durable gene regulation
    BOSTON, May 2, 2023 /PRNewswire/ -- Chroma Medicine , Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced two oral data presentations that showcase the potential of its epigenetic editing platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16-20, 2023 in Los Angeles, California.
  • The presentations include the first in vivo proof-of-concept data for Chroma's epigenetic editing platform along with data demonstrating the key advantages of epigenetic editing for multiplex gene regulation.
  • Chroma plans to release data from additional pipeline programs at upcoming scientific conferences.
  • Data presented at ASGCT demonstrate the ability of epigenetic editors to facilitate genotoxicity-free multiplexed editing in healthy donor-derived T cells, as compared to Cas9-mediated editing.

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

Retrieved on: 
Thursday, April 20, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Precision BioSciences, DNA, Gene editing, Hepatitis B virus, Hepatocyte, HBsAg, Chromosomal translocation, CccDNA, HBV, Hepatitis, Genome, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program.
  • PBGENE-HBV is designed to potentially eliminate hepatitis B virus (HBV) by targeting viral covalently closed circular DNA (cccDNA) in vivo.
  • An abstract relating to the PBGENE-HBV program was selected for an oral presentation at the Global Hepatitis Summit 2023, being held April 25-28, 2023 in Paris, France.
  • “Specificity is paramount for a safe gene editing approach to eliminate hepatitis B virus,” said Jeff Smith, Chief Research Officer of Precision BioSciences.